Company Description
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States.
It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients.
The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa.
The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023.
PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.
| Country | France |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Eric Soyer Ph.D. |
Contact Details
Address: 60 Avenue Rockefeller, Batiment Adenine Lyon, I0 69008 France | |
| Phone | 011-33-4-78-74-44-38 |
| Website | erytech.com |
Stock Details
| Ticker Symbol | PHXM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001624422 |
| ISIN Number | US29604W2070 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Eric Soyer Ph.D. | Deputy Chief Executive Officer, Deputy GM, Chief Financial Officer and Chief Operating Officer |
| Dr. Jérôme Bailly Pharm.D. | Deputy Chief Executive Officer, Deputy GM, Chief Quality Officer and Qualified Person |
| Thibaut du Fayet | Chief Executive Officer |
| Céline Breda | Chief Technology Officer |
| Cindy Fevre | Chief Scientific Officer |
| Naomi Eichenbaum | Director Investor Relations |
| Anne-Cécile Fumey | Vice President of Human Resources |
| Karine Charton Ph.D. | Chief Business Officer |
| Dr. Pascal Birman M.D. | Chief Medical Officer |
| Frederique Vieville | Chief Regulatory Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 11, 2024 | 15F-12B | Filing |
| Mar 5, 2024 | EFFECT | Notice of Effectiveness |
| Mar 4, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Mar 4, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Mar 4, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Mar 4, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Mar 4, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Mar 4, 2024 | POS AM | Post-Effective amendments for registration statement |
| Mar 1, 2024 | 25 | Filing |
| Feb 21, 2024 | 6-K | Report of foreign issuer |